Cipla

In 1924, a young chemistry graduate from Aligarh applied for a passport to study in Germany. The British District Magistrate refused him, citing his political activities. He pushed back, got the passport, finished his PhD at Berlin University, and on the return voyage to India in 1928 made the decision that would define the next century of Indian pharmaceutical industry.

The country, he decided, did not need another British-trained chemist returning to a comfortable academic post. It needed a chemical research institute that could train Indian graduates and manufacture the medicines Indians actually used. Dr. Khwaja Abdul Hamied was 29.

A 1935 founding and a 1939 visit

In 1935, Hamied founded The Chemical, Industrial and Pharmaceutical Laboratories in Bombay. He gave the company every patent and proprietary formula he owned, without taking a single rupee in royalty. The acronym would carry the name from there: CIPLA.

On 4 July 1939, the visit came that would define Cipla's identity for the next eighty years. Mahatma Gandhi walked into the Cipla factory in Bombay and asked Hamied a direct question: with war ahead and import supply lines threatened, could an Indian company actually make the medicines India needed? Hamied said yes. Through World War II, Cipla filled the gap.

Hamied served on the Bombay Legislative Council from 1937 to 1962, refused a Muslim minister's role in the Bombay cabinet, and served as Sheriff of Bombay. The political and the commercial sat side by side; the company was a national-purpose project as much as a business.

A 2001 phone call

Sixty-six years later, on the night of 6 February 2001, Yusuf K. Hamied, the founder's son and long-time chairman, was at a dinner party in Mumbai when his phone rang. Donald McNeil, a reporter for the New York Times, had heard at his own dinner table that Cipla intended to sell HIV/AIDS antiretrovirals to African countries and aid groups at about $350 a year per patient.

The global standard price was about $10,000 to $12,000 a year. One thirtieth.

Hamied confirmed it on the phone. McNeil's reply, by his own account: "Dr. Hamied, your life will not be the same from tomorrow." The story ran on the front page the next morning.

What followed reshaped global drug-access policy. By year-end, world leaders had created the Global Fund to Fight AIDS, Tuberculosis and Malaria; on 14 November 2001 the WTO adopted the Doha Declaration on TRIPS, giving developing countries the right to issue compulsory licenses for essential medicines. The price of antiretroviral treatment has since fallen to about 20 cents per day. More than six million people in the developing world now receive treatment, up from about 2,000 in 2001.

The same operational conviction that brought Mahatma Gandhi to a Bombay factory in 1939 had been applied, sixty-six years later, to a different problem at a global scale.

Why the commercial engine is the interesting part

By FY2025 Cipla reports total income of about ₹27,548 crore, EBITDA of ~₹7,128 crore (25.9% margin) and net profit of ~₹5,273 crore, up about 28.4% year on year. The US business reached an all-time high of US$934 million. Umang Vohra is Managing Director and Global CEO; the Hamied family remains the anchor.

Underneath the consolidated number sits an operating reality harder than the legacy headlines suggest. Cipla runs two engines under one P&L. The Indian branded business is anchored on respiratory and chronic care, with one of the country's deepest specialist-detailing footprints; the open question is whether that intensity holds as chronic-care complexity grows. The US business is increasingly specialty-mixed, a respiratory specialty franchise being built alongside the legacy regulated-generics base; the open question there is filings cadence, payer access and pricing discipline in price-erosion-heavy segments.

What the 1935 founding and the 2001 AIDS announcement had in common was operational clarity at a moment of decision. The next chapter turns on whether that clarity can be applied not to a single watershed decision, but to the daily call-by-call execution that decides a pharma quarter today.

The next chapter

The Cipla story we have told ourselves for nine decades is a story of access: access to medicine, access to chemistry, access for the developing world. The next chapter is not less moral, more operational. Can every respiratory rep walking into a pulmonologist's chamber know what shifted in this prescriber's inhaler share this fortnight, before the call? Can leadership move from reviewing a multi-engine portfolio in dashboards to acting on the few decisions that actually move the quarter?

It will not be more dashboards. The next advantage is intelligence. The first generation of Indian pharma built access. The second built scale. The next will build intelligent commercial operations. That is the future PharmaOS is built for.